SMART PHONE APPS DETECTS BACTERIA DISEASES

In much the same way that glucometers and pregnancy tests have revolutionized in-home diagnostic testing, researchers from Florida Atlantic University and collaborators have identified a new biosensing platform that could be used to remotely detect and determine treatment options for HIV, E-coli, Staphylococcus aureas and other bacteria. Using a drop of blood from a fingerprick, this novel biosensing platform provides clinically relevant specificity, sensitivity and detection of pathogens from whole blood and plasma.

The thin, lightweight and flexible materials developed by these researchers can be fabricated and operated without the need for expensive infrastructure and skilled personnel, potentially solving real-world healthcare problems for both developed and developing countries. Using this technology, they also have developed a phone app that could detect bacteria and disease in the blood using images from a cellphone that could easily be analyzed from anywhere in the world.

Waseem Asghar, Ph.D., assistant professor of electrical engineering in the College of Engineering and Computer Science at FAU, co-first author on the study, along with Hadi Shafiee, Ph.D., instructor in medicine at the Division of Biomedical Engineering at Brigham and Women's Hospital, Harvard Medical School; Fatih Inci, Ph.D.; and Utkan Demirci, Ph.D., Stanford School of Medicine, senior authors on the study, have published their findings in Nature Scientific Reports in an article titled "Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets." Other team members on the study include Mehmet Yuksekkaya, Ph.D.; Muntasir Jahangir; Michael H. Zhang; Naside Gozde Durmus, Ph.D.; Umut Atakan Gurkan, Ph.D., and Daniel R. Kuritzkes, M.D.

In the article, the researchers address the limitations of current paper and flexible material-based platforms and explain how they have integrated cellulose paper and flexible polyester films as new diagnostic tools to detect bioagents in whole blood, serum and peritoneal fluid. They employed three different paper and flexible material-based platforms incorporated with electrical and optical sensing modalities. They were able to demonstrate how these new materials can be widely applied to a variety of settings including medical diagnostic and biology laboratories.

Using paper and flexible substrates as materials for biosensors, Asghar and his colleagues have identified a new rapid and cost-effective way to diagnose diseases and monitor treatment in point-of-care settings. They have been able to show how their new platforms are uniquely able to isolate and detect multiple biotargets selectively, sensitively, and repeatedly from diverse biological mediums using antibodies.

"There is a dire need for robust, portable, disposable and inexpensive biosensing platforms for clinical care, especially in developing countries with limited resources," said Asghar.

Existing paper and flexible material-based platforms use colorimetric, fluorometric and electrochemical approaches that require complex labeling steps to amplify their signal, are very costly to fabricate and also require expensive equipment and infrastructure.

"The future of diagnostics and health monitoring will have potentially cell-phone based or portable readers sipping saliva or blood and continuously monitoring human health taking it way beyond where we are with counting steps today," said Demirci, who is the corresponding author.

Asghar notes that because their materials are easy to make, easy to use, and can easily and safely be disposed by burning, they provide appealing strategies for developing affordable tools that have broad applications such as drug development, food safety, environmental monitoring, veterinary medicine and diagnosing infectious diseases in developing countries.

"Our paper microchip technologies can potentially have a significant impact on infectious diseases management in low- and middle-income countries where there is limited laboratory infrastructure," said Shafiee.

Demirci notes that these platforms could potentially be adapted and tailored to detect other pathogens and biotargets with well-known biomarkers.

SWEAT EATING BACTERIA MAY IMPROVE SKIN HEALTH

Bacteria that metabolize ammonia, a major component of sweat, may improve skin health and some day could be used for the treatment of skin disorders, such as acne or chronic wounds. In a study conducted by AOBiome LLC, human volunteers using the bacteria reported better skin condition and appearance compared with a placebo control group. The researchers presented the study results at the 5th ASM Conference on Beneficial Microbes in Washington, DC

Ammonia-oxidizing bacteria (AOB) are ubiquitous in soil and water and are essential components of the nitrogen cycle and environmental nitrification processes. The researchers hypothesized that AOB are uniquely suited for the environment of the human skin because ammonia oxidation products, nitrite and nitric oxide, play important roles in physiological functions of the skin, including inflammation, blood vessel relaxation and wound healing. AOB may also improve the skin microenvironment by driving a lower pH through ammonia consumption.

For the study, the researchers used a strain of Nitrosomonas eutropha isolated from organic soil samples. In the blinded, placebo-controlled, study involving 24 volunteers, one group applied a suspension of the live bacteria on their face and scalp for one week, while a second group used placebo. Both groups were followed for an additional two weeks. Subjects did not use hair products during the first and second week and they returned to their normal routine for the third week.

The AOB users reported qualitative improvements in skin condition compared with no or minimal improvement reported by the control group. Use of a bacterial DNA detection assay demonstrated the presence of AOB in 83-100 percent of skin swabs obtained from AOB users during or immediately after completion of the one-week application period, and in 60 percent of the users on Day 14, but not in any of the placebo control samples. Surprisingly, in this small study, the improvement among the AOB users correlated with the levels of AOB on their skin. Neither group had AOB on their skin at the start of the study. Further analysis suggested potential modulation of the skin microbiota by AOB. Importantly, there were no adverse events associated with the topical application of AOB.

"This study shows that live Nitrosomonas are well tolerated and may hold promise as novel, self-regulating topical delivery agents of nitrite and nitric oxide to the human skin," said Dr. Larry Weiss, AOBiome's Chief Medical Officer. "Our next step is to conduct clinical trials to assess the therapeutic potential of AOB in patients with acne or diabetic ulcers."